Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

August 11, 2017: By Jon Swedien

Allegro logoAllegro Ophthalmics on Aug. 9 reported positive results from its Phase IIb Stage 2 clinical trial for Luminate.

Luminate—a first-in-class integrin peptide therapy that treats neovascular retinal diseases—met its primary endpoint when used as a sequential therapy in patients with diabetic macular edema (DME) in the DEL MAR Stage 2 study, according to the San Juan Capistrano, California, company.

The primary endpoint was non-inferiority to bevacizumab in mean change in best-corrected visual acuity (BCVA) at 20 weeks when Luminate was used with a single bevacizumab pretreatment (sequential therapy) or in combination with bevacizumab.

The Luminate results were achieved after one treatment of 1.25 mg bevacizumab (week zero) followed by three 1 mg Luminate injections (weeks one, four, and eight) and 12 weeks off treatment, compared with five injections given every four weeks with bevacizumab.

The data showed the mean gain in BCVA was 7.1 letters for patients in the Luminate with bevacizumab pretreatment (sequential) group compared with 6.7 letters for patients in the bevacizumab control group.

The double-masked, placebo-controlled, randomized, multicenter, five-month Phase IIb, Stage 2 trial, conducted at 14 US sites, included five arms:

— Luminate 0.5 mg or 1.0 mg as a sequential therapy after a single treatment of 1.25 mg bevacizumab (week zero) followed by three Luminate injections (weeks one, four, and eight), and 12 weeks off treatment;

— Luminate 0.5 mg or 1.0 mg given in direct combination with bevacizumab 1.25 mg at weeks one, four, and eight, and 12 weeks off treatment;

— A 1.25 mg bevacizumab control arm of five monthly injections.

The trial also found that Luminate was well-tolerated with no drug toxicity or intraocular inflammation. These safety results are consistent with previously conducted Luminate studies on human subjects where there were no reports of significant inflammation and no evidence of retinal tears or detachments.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023